A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study.
Bruno Daniele(Azienda Ospedaliera G.Rummo), Federica Perrone(University of Bari Aldo Moro), Giuseppe Cabibbo(Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo), Alessandro Granito(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), Giacomo Cartenì(Ospedale Antonio Cardarelli), M. Angélico, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Mario Roselli(University of Rome Tor Vergata), Gennaro Daniele(Università Cattolica del Sacro Cuore), Gabriele Missale(University of Parma), Antonio Craxı̀(University of Palermo), Giovan Giuseppe Di Costanzo(Azienda di Rilievo Nazionale ed Alta Specializzazione), Massimo Di Maïo(University of Siena), Luigi Bolondi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Ciro Gallo(University of Campania "Luigi Vanvitelli")
Cited by 4
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k